Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma: NCT07699757 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Not yet recruiting
Recruitment status
258
Planned enrollment
2029-04-01
Primary-completion proxy
Executive view
NCT07699757 evaluates Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma. The disclosed sponsor is Haisco Pharmaceutical Group Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is DLTs, assessed over 21 days for NSCLC cohorts; 28 days for PDAC cohorts.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07699757 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Pancreatic Ductal Adenocarcinoma landscape. Drug & Asset MCP drug_fetch was queried for Albumin-Bound Paclitaxel, while Company & Deal Intelligence MCP organization_fetch was queried for Haisco Pharmaceutical Group Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07699757 | Albumin-Bound Paclitaxel | Phase 1 / Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | China | DLTs 21 days for NSCLC cohorts; 28 days for PDAC cohorts | 2029-04-01 |
| NCT07683221 | Ipilimumab | Phase 2 / Not yet recruiting | Shandong First Medical University Affiliated Tumor Hospital (Shandong Cancer Research Institute Shandong Tumor Hospital) | China | Progression-Free Survival (PFS) From initiation of study treatment until disease progression or death… | 2029-07-15 |
| NCT07649928 | ES502 | Early Phase 1 / Recruiting | Ruijin Hospital | China | To evaluate the safety and tolerability of ES502 in subjects with advanced solid tumors 2 years | 2028-12-01 |
| NCT07650357 | CLSP-5282 | Phase 1 / Not yet recruiting | Clasp Therapeutics, Inc. | United States | Part A Monotherapy Dose Escalation 28 days after infusion | 2029-05-01 |
| NCT07645651 | Samuraciclib hydrochloride | Phase 1 / Recruiting | University of Washington | United States | Change in ribonucleic acid polymerase II serine levels Within 72 hours post versus pre-samuraciclib treatment | 2027-07-14 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07699757 is a Phase 1, not yet recruiting study with 258 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Factorial Assignment.
The primary endpoint is “DLTs” over “21 days for NSCLC cohorts; 28 days for PDAC cohorts.” The retrieved endpoint description is: DLTs assessed during the protocol-defined DLT evaluation period..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 258 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Pancreatic Ductal Adenocarcinoma. These records do not establish direct evidence for NCT07699757 unless the registration number matches.
Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
Phase 2; n=32; ORR = 0.06 Proportion of participants (95% Confidence Interval, 0.00 - 0.27) Source: https://clinicaltrials.gov/ct2/show/results/NCT04820179
A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/…
Phase 2; n=32; Proportion of Participants With an Overall Response = 0.35 proportion of participants (90% Confidence Interval, 0.20 - 0.52); Proportion of Participants With an Overall Response = 0 proportion of participants (90% Confidence Interval, 0 - 0.63) Source: https://clinicaltrials.gov/ct2/show/results/NCT03457948
A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pan…
Phase 2; n=12; Percentage of Participants With Objective Response Rate = 8.3 Percent of participants (95% Confidence Interval, 0.2 - 38.5) Source: https://clinicaltrials.gov/ct2/show/results/NCT05997056
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Albumin-Bound Paclitaxel is indexed as Chemical drugs with Tubulin biology and a global stage of Approved. The asset profile lists CSPC Pharmaceutical Group Ltd. as an originator or developer.
Haisco Pharmaceutical Group Co., Ltd. is indexed in China with the website http://www.haisco.com. Haisco Pharmaceutical Group is a Chinese healthcare company focused on the research and development of therapeutic drugs. The record lists 61 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Albumin-Bound Paclitaxel is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07699757
Protocol source: https://clinicaltrials.gov/study/NCT07699757
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes DLTs and 2029-04-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
